Key facts
- This page summarizes Ronald B. Moss's Form 4 filing for Adamis Pharmaceuticals Corp.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Mar 2022, 18:39.
Ronald B. Moss - 18 Mar 2022 Form 4 Insider Report for Adamis Pharmaceuticals Corp
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 18 Mar 2022
- Net transaction value
- -$4,949
- SEC form
- 4
- Accepted by SEC
- 22 Mar 2022, 18:39:54 UTC
- Prior SEC filing
- 03 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David C. Benedicto, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ronald B. Moss filed Form 4 for Adamis Pharmaceuticals Corp on 22 Mar 2022.
Change
- Previous filing in this sequence was filed on 03 Dec 2021.
- Current net transaction value: -$4,949.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADMP
transaction
Common Stock
Sale
- Transaction value
- $4,949
- Shares
- -8,199
- Change %
- -3.9%
- Price
- $0.6036
- Shares after
- 201,911
- Date
- 18 Mar 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to pay the withholding and tax obligations relating to the issuance of shares following the vesting of RSUs previously granted to the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5954 to $0.6143, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.